|
Disease-free survival as a predictor of overall survival in localized renal cell carcinoma (RCC) following first nephrectomy. |
|
|
Consulting or Advisory Role - AVEO; Calithera Biosciences; Eisai; Exelixis; Merck Sharp & Dohme; Pfizer; Roche/Genentech |
Expert Testimony - Lilly (I) |
|
|
Consulting or Advisory Role - Merck Sharp & Dohme |
|
Jaqueline Willemann Rogerio |
Employment - Merck Sharp & Dohme |
Stock and Other Ownership Interests - Merck Sharp & Dohme |
|
|
Consulting or Advisory Role - Merck Sharp & Dohme |
|
|
Employment - Merck Sharp & Dohme |
|
|
Consulting or Advisory Role - Merck Sharp & Dohme |
|
|
Consulting or Advisory Role - Merck Sharp & Dohme |
|
|
Employment - Merck Sharp & Dohme |
|
|
Consulting or Advisory Role - Merck Sharp & Dohme |
|
|
No Relationships to Disclose |